Back to discover
Disease
Meningioma
Late-stage therapeutic developmentEmerging research
1
Publications
22
Clinical trials
2021
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
EANO guideline on the diagnosis and management of meningiomas.
Research2021-11-01Neuro-oncology
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 6 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
- Q1 2027A Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma
- Q1 2027Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
- Q2 2027177Lu-DOTATATE for Recurrent Meningioma: a Randomized Phase II Study
- Q3 2027A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- Q1 2028A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Major developments
Major trial resultsHigh impact
Results posted2026-05-18
Upcoming trial readoutHigh impact
Results expected Q1 20272026-07-02
Clinical MilestonesViewHide
Results posted
Results expected
- 2026-07-02Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway MutationsResults expected Q1 2027
- 2026-06-24A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaResults expected Q1 2028
- 2026-06-15177Lu-DOTATATE for Recurrent Meningioma: a Randomized Phase II StudyResults expected Q2 2027
- 2026-04-22A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation TherapyResults expected Q3 2027
- 2026-04-15A Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent MeningiomaResults expected Q1 2027
Other updates
- 2027-04-01A Pilot Study, Open-Label Study of ONC201 for Refractory MeningiomaWithdrawn
Activity timeline8
- 2027-04-01ClinicalA Pilot Study, Open-Label Study of ONC201 for Refractory MeningiomaWithdrawn
- 2026-07-02ClinicalPhase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway MutationsResults expected Q1 2027
- 2026-06-24ClinicalA Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaResults expected Q1 2028
- 2026-06-15Clinical177Lu-DOTATATE for Recurrent Meningioma: a Randomized Phase II StudyResults expected Q2 2027
- 2026-05-18ClinicalA Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent MeningiomasResults posted
- 2026-04-22ClinicalA Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation TherapyResults expected Q3 2027
- 2026-04-15ClinicalA Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent MeningiomaResults expected Q1 2027
- 2026-03-13ClinicalA Phase 2 Multicenter, Double-blind, Randomized-controlled Study of Abemaciclib (CDK4 and 6 Inhibitor) in Newly Diagnosed RB-proficient Grade 3 Meningioma ParticipantsResults expected Q3 2028
Clinical trials
The current development programme across all trial phases.
Clinical programme
22
6
2
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Recent publications
Major themes3
- Meningeal Neoplasms1
- Meningioma1
- Radiosurgery1
Leading journals1
- Neuro-oncology1
Leading researchers8
- Goldbrunner R1
- Houdart E1
- Jenkinson MD1
- Le Rhun E1
- Lefranc F1
- Lund-Johansen M1
- Mawrin C1
- Minniti G1
Affiliations (unnormalised)6
- Amphia Hospital1
- Bergen University Hospital1
- Center for Neurooncology1
- Center for Proton Therapy1
- Center of Neurosurgery1
- City of Health and Science University Hospital1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.